Clinical Trials · NCT05582096
A Study of LY3457263 in Obese Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 38
- Start date
- Nov 2022
- Locations
- 1 site, United States
- Primary endpoint
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration